Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare receives expert backing for Skinoren

Bayer HealthCare receives expert backing for Skinoren

20th January 2011

Bayer HealthCare has highlighted new research that underlines the effectiveness of its product Skinoren in treating the skin condition rosacea.

A recent consensus paper from the Rosacea International Expert group has outlined new recommendations for the treatment of the disease, endorsing symptomatic and evidence-oriented decision-making rather than therapy based on prior subtype classification.

It stated that the azelaic acid-based Skinoren, which is marketed by the Bayer HealthCare subsidiary Intendis, can be an effective topical monotherapy under these guidelines.

The treatment's efficacy in reducing papulopustular lesions and ameliorating persistent erythema was highlighted as a key advantage, as well as its ability to be combined with oral antibiotics.

Bayer HealthCare added: "Azelaic acid has a favourable tolerability profile which promotes good patient compliance and low discontinuation rates."

Earlier this week, the company announced the commencement of a new clinical study of its drug VEGF Trap-Eye among sufferers of choroidal neovascularisation of the retina caused by pathologic myopia.ADNFCR-8000103-ID-800353813-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.